Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | PGR | P06401 | 4/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL6 | P05231 | 1/20 | 0.56 |
| ▸ | GLUL | P15104 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084683 | 0.98 | HIF1A (0.62) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL141852 | 0.98 | HIF1A (0.63) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL2087489 | 0.98 | HIF1A (0.63) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL7142715 | 0.98 | HIF1A (0.63) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL7137204 | 0.98 | HIF1A (0.63) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL3488313 | 0.98 | HIF1A (0.63) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL1535104 | 0.97 | HIF1A (0.63) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL141828 | 0.96 | HIF1A (0.62) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| SCHEMBL4450350 | 0.95 | HIF1A (0.61) | HIF1ANR3C2NR3C1HSD17B10PGR | |
| Water SCHEMBL27961624 | 0.95 | HIF1A (0.61) | HIF1ANR3C2NR3C1HSD17B10PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 951 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352645-B2 | Compositions and methods for treating Leber's hereditary optic neuropathy | Wuhan Neurophth Biotechnology Limited Company (CN) | 2022-06-07 | — | — | US | claimed |
| EP-3840785-A1 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | Wuhan Neurophth Biotechnology Limited Company (CN) | 2021-06-30 | — | — | EP | claimed |
| US-20210189429-A1 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | Wuhan Neurophth Biotechnology Limited Company (CN) | 2021-06-24 | — | — | US | claimed |
| CN-112584874-A | Compositions and methods for treating leber's hereditary optic neuropathy | 武汉纽福斯生物科技有限公司 | 2021-03-30 | — | — | CN | claimed |
| WO-2020038352-A1 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | WUHAN NEUROPHTH BIOLOGICAL TECHNOLOGY LIMITED COMPANY (CN) | 2020-02-27 | — | — | WO | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120028910-A1 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS | FOVEA PHARMACEUTICALS (FR) | 2012-02-02 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| US-7745138-B2 | Methods for determining drug responsiveness | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-06-29 | — | — | US | claimed |
| EP-2117556-A2 | COMBINATION THERAPY COMPRISING ROMIDEPSIN AND I.A. BORTEZOMIB | Gloucester Pharmaceuticals, Inc. (US) | 2009-11-18 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090105200-A1 | Combination therapy | GLOUCESTER PHARMACEUTICALS | 2009-04-23 | — | — | US | claimed |
| WO-2008091620-A2 | COMBINATION THERAPY COMPRISING ROMIDEPSIN AND I.A. BORTEZOMIB | GLOUCESTER PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| US-6878518-B2 | Methods for determining steroid responsiveness | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-04-12 | — | — | US | claimed |
| US-20040203031-A1 | Methods for determining drug responsiveness | UNIVERSITY OF PENNSYLVANIA | 2004-10-14 | — | — | US | claimed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | claimed |
| WO-2003062792-A2 | METHODS FOR DETERMINING DRUG RESPONSIVENESS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-07-31 | — | — | WO | claimed |
| US-20030138781-A1 | Methods for determining steroid responsiveness | UNIVERSITY OF PENNSYLVANIA | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105200-A1 | Combination therapy | MCL1, BCL3, PSMB5 | HIF1A 3574/4885NR3C2 758/4885NR3C1 480/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | HIF1A 1602/4885NR3C2 796/4885NR3C1 413/4885 |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | OPRM1, OPRK1, OPRD1 | HIF1A 404/4885NR3C2 1294/4885NR3C1 1319/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | HIF1A 1602/4885NR3C2 796/4885NR3C1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.